MYOPATHY CAUSED BY THE INTERACTION OF COLCHICINE AND STATINS
A. S. Kazakov,
M. A. Darmostukova,
T. M. Bukatina,
I. I. Snegireva,
V. K. Lepakhin,
K. E. Zatolochina https://doi.org/10.30895/2312-7821-2018-6-3-118-122
Abstract
Myopathy is a life-threatening disease that can be caused, among other things, by the intake of various medications. Despite the fact that many drug-induced myopathies are well known, however, many health professionals are not alert to myopathies caused by drug interactions. Myopathy is a wellknown adverse reaction of statins, and muscle damage can range from minor muscle pain and weakness to life-threatening rhabdomyolysis. Colchicine can also cause myopathy, including rhabdomyolysis. The combination of colchicine and statins can significantly increase the risk of myopathy compared with their intake separately. In cases of development of myopathy in patients receiving colchicine and statins simultaneously, the most common manifestation of drug interaction was muscle weakness, occurring in almost every case, and in some cases, muscle weakness was so severe that the patient lost the ability to move. In a third of cases, the development of muscle weakness was accompanied by muscular pain, and darkening of urine to tea shade. One study showed that 40 % of patients received concurrent combinations of drugs that increased the risk of muscle damage. It is concluded that the simultaneous administration of colchicine and statins requires an assessment of the “benefit-risk” ratio, as well as the administration of drugs in minimally effective doses.
About the Authors
A. S. Kazakov
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
8/2 Petrovsky Blvd, Moscow 127051, Russian Federation
Leading Analyst of the Department of Expert Analysis Methodology. PhD
M. A. Darmostukova
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
8/2 Petrovsky Blvd, Moscow 127051, Russian Federation
Senior Analyst Department for Evaluation of MIBPs Side Effects of the DEMPS
T. M. Bukatina
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
8/2 Petrovsky Blvd, Moscow 127051, Russian Federation
Senior Analyst of Department of Expert Analysis Methodology of the DEMPS. PhD
I. I. Snegireva
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
8/2 Petrovsky Blvd, Moscow 127051, Russian Federation
Head of Department for Evaluation of MIBPs Side Effects of the DEMPS. PhD
V. K. Lepakhin
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Russian Federation
8/2 Petrovsky Blvd, Moscow 127051, Russian Federation
Chief Expert of Department of Expert Analysis Methodology of the DEMPS. MD, PhS, DSc (Med), Prof.
K. E. Zatolochina
Peoples’ Friendship University of Russia
Russian Federation
Russian Federation
6 Miklukho-Maklaya str., Moscow, 117198, Russian Federation
Assoc. prof. PhD.
References
1. Американская «Ассоциация мышечной дистрофии» (MDA); 2018 [процитировано 20 июня 2018]. Доступно на: https://www.mda.org
2. Центр нервно-мышечных заболеваний Washington University ( Neuromuscular Disease Center); 2018 [процитировано 20 июня 2018]. Доступно на: https://neuromuscular.wustl.edu/index.html
3. Hsu W-C, Chen WH, Chang MT, Chiu HC. Colchicine- induced acute myopathy in a patient with concomitant use of simvastatin. Clin Neuropharmacol. 2002;25(5):266–8.
4. Baker SK, Goodwin S, Sur M, Tarnopolsky MA. Cytoskeletal myotoxicity from simvastatin and colchicine. Muscle Nerve. 2004;30(6):799–802. DOI: 10.1002/mus.20135
5. Justiniano M, Dold S, Espinoza SR. Rapid onset of muscle weakness (rhabdomyolysis) associated with the combined use of simvastatin and colchicine. J Clin Rheumatol. 2007;13(5):266–8. DOI: 10.1097/RHU.0b013e318156d977
6. Sahin G, Korkmaz C, Yalcin AU. Which statin should be used together with colchicine? Clinical experience in three patients with nephrotic syndrome due to AA type amyloidosis. Rheumatol Int. 2008;28(3):289– 91. DOI: 10.1007/s00296-007-0435-1
7. Francis L, Bonilla E, Soforo E, et al. Fatal toxic myopathy attributed to propofol, methylprednisolone, and cyclosporine after prior exposure to colchicine and simvastatin. Clin Rheumatol. 2008;27(1):129– 31. DOI: 10.1007/s10067-007-0696-9
8. Tufan A, Dede DS, Cavus S, Altintas ND, Iskit AB, Topeli A. Rhabdomyolysis in a patient treated with colchicine and atorvastatin. Ann Pharmacother. 2006;40(7–8):1466–9. DOI: 10.1345/aph.1H064
9. Phanish MK, Krishnamurthy S, Bloodworth LL. Colchicine-induced rhabdomyolysis. Am J Med. 2003;114(2):166–7.
10. Vasudevan AR, Uthamalingam S, Kumar S, Tamarin F, Brensilver JM. Colchicine-induced rhabdomyolysis: the whole is greater than the sum of its parts!. Am J Med. 2003;115(3):249.
11. Torgovnick J, Sethi N, Arsura E. Colchicine and HMG Co-A reductase inhibitors induced myopathy — a case report. Neurotoxicology. 2006;27(6):1126–7. DOI: 10.1016/j.neuro.2006.09.003
12. Atasoyu EM, Evrenkaya TR, Solmazgul E. Possible colchicine rhabdomyolysis in a fluvastatin-treated patient. Ann Pharmacother. 2005;39(7–8):1368–9. DOI: 10.1345/aph.1E653
13. Sarullo FM, Americo L, Di Franco A, Di Pasquale P. Rhabdomyolysis induced by co- administration of fluvastatin and colchicine. Monaldi Arch Chest Dis. 2010;74(3):147–9. DOI: 10.4081/monaldi.2010.264
14. Alayi G, Cengiz K, Canturk F, Durmus D, Akyol Y, Menekse EB. Acute myopathy in a patient with concomitant use of pravastatin and colchicine. Ann Pharmacother. 2005;39(7– 8):1358–61. DOI: 10.1345/aph.1E593
15. Bouquié R, Deslandes G, Renaud C, Dailly E, Haloun A, Jolliet P. Colchicine-induced rhabdomyolysis in a heart/lung transplant patient with concurrent use of cyclosporin, pravastatin, and azithromycin. J Clin Rheumatol. 2011;17(1):28– 30. DOI: 10.1097/RHU.0b013e3182056042
16. Boonmuang P, Nathisuwan S, Chaiyakunapruk N, et al. Characterization of statin- associated myopathy case reports in Thailand using the health product vigilance center database. Drug Saf. 2013;36(9):779– 87. DOI: 10.1007/s40264-013-0055-5
17. Siriangkhawut M, Tansakul P, Uchaipichat V. Prevalence of potential drug interactions in Thai patients receiving simvastatin: the causality assessment of musculoskeletal adverse events induced by statin interaction. Saudi Pharm J. 2017;25(6):823– 9. DOI: 10.1016/j.jsps.2016.12.006
18. Лиджиева АА, Смолярчук ЕА, Кокорина АЕ, Смирнов ВВ, Егоренков ЕА. Использование биотехнологических препаратов как способ повышения безопасности фармакотерапии: современное состояние проблемы и перспективы развития. БИОпрепараты. Профилактика, диагностика, лечение. 2016;16(3):145–50. [Lidzhieva AA, Smolyarchuk EA, Kokorina AE, Smirnov VV, Egorenkov EA. Biotechnological preparations as a means of improving the safety of pharmacotherapy: state of the art and prospects of development. BIOpreparaty. Profilaktika, diagnostika, lechenie = BIOpreparations. Prevention, Diagnosis, Treatment. 2016;16(3):145–50 (In Russ.)]. https://doi.org/10.30895/2221-996X-2016-16-3-145-150
19. Олефир ЮВ, Медуницын НВ, Авдеева ЖИ, Солдатов АА, Мовсесянц АА, Меркулов ВА, Бондарев ВП. Современные биологические/биотехнологические лекарственные препараты. Актуальные вопросы разработки и перспективы использования. БИОпрепараты. Профилактика, диагностика, лечение. 2016;16(2):67–77. [Olefir YuV, Medunitsyn NV, Avdeeva ZI, Soldatov AA, Movsesyants AA, Merkulov VA, Bondarev VP. Modern biological/biotechnological medicinal products. Topical issues and prospects for development. BIOpreparaty. Profilaktika, diagnostika, lechenie = BIOpreparations. Prevention, Diagnosis, Treatment. 2016;16(2):67–77 (In Russ.)]. https://doi.org/10.30895/2221-996X-2016-16-2-67-77
20. Олефир ЮВ, Меркулов ВА, Соловьев ЕА, Устюгова ЕА, Саяпина ЛВ, Бондарев ВП. Опыт российского и зарубежного законодательства в области регулирования внесения пострегистрационных изменений в досье на лекарственные препараты. Ведомости Научного центра экспертизы средств медицинского применения. 2015; (4):11–5. [Olefir YuV, Merkulov VA, Soloviev EA, Ustyugova EA, Sayapina LV, Bondarev VP. Russian and foreign legislation on regulation of post approval variations in the dossier for the medicinal products. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2015;(4):11–5 (In Russ.)]
Review
For citations:
Kazakov A.S., Darmostukova M.A., Bukatina T.M., Snegireva I.I., Lepakhin V.K., Zatolochina K.E. MYOPATHY CAUSED BY THE INTERACTION OF COLCHICINE AND STATINS. Safety and Risk of Pharmacotherapy. 2018;6(3):118-122. (In Russ.) https://doi.org/10.30895/2312-7821-2018-6-3-118-122
Views:
5138
Email this article 